Epistem and sanofi-aventis enter a three year research collaboration to use Epistem's biomarker gene expression profiling and immunohistochemistry technologies to support sanofi-aventis' cancer program

Epistem Holdings plc

U.K. / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

sanofi-aventis Group

France / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced